Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
45 hedge funds and large institutions have $120M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
17% more capital invested
Capital invested by funds: $102M → $120M (+$17.7M)
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
20% less funds holding
Funds holding: 56 → 45 (-11)
73% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.03M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$2.06M |
| 3 |
Handelsbanken Fonder
Stockholm,
Sweden
|
+$878K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$233K |
| 5 |
BlackRock
New York
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHAM
Folger Hill Asset Management
New York
|
-$2.1M |
| 2 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$1.67M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$955K |
| 4 |
Renaissance Technologies
New York
|
-$719K |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$580K |
FOMX Hedge Fund Activity: Q3 2017 in Review
45 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q3 2017, worth a combined $120M — up 17% from $102M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of FOMX and 4 opened new positions — a net loss of 11 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, adding an estimated $3.03M. The largest seller was Folger Hill Asset Management, exiting entirely with an estimated $2.1M sold.
- 45 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q3 2017, down from 56 in Q2 2017.
- Funds reported $120M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q3 2017, up 17% quarter-over-quarter.
- 4 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q3 2017 and 15 closed out, a net change of -11 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q3 2017 was Millennium Management, an estimated $3.03M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q3 2017 was Folger Hill Asset Management, an estimated $2.1M sold.
Based on aggregated 13F filings for Q3 2017.